Literature DB >> 22335632

Lack of standardization in exception points for patients with primary sclerosing cholangitis and bacterial cholangitis.

D Goldberg1, T Bittermann, G Makar.   

Abstract

For conditions that the Model for End-Stage Liver Disease (MELD) score does not accurately predict waitlist mortality, transplant centers may apply to regional review boards for exception points. For patients with primary sclerosing cholangitis (PSC) suffering from bacterial cholangitis, consensus recommendations published in December 2006 are to grant exception points for recurrent cholangitis with ≥ 2 episodes of bacteremia or ≥ 1 episode septic complications. Using data provided by the United Network for Organ Sharing, we evaluated PSC patients who applied for exception points due to bacterial cholangitis from February 27, 2002 to March 14, 2011. Before publication of the recommendations, 66.0% of applications were accepted, compared with 80.1% after (p < 0.001). Focusing on applications after publication of the recommendations, 311 (74.6%) did not meet the recommended criteria, and 250 (80.4%) of these were approved. Of patients with approved applications, those not meeting consensus criteria were more likely to be transplanted, (77.4% vs. 62.8%, p = 0.043), whereas those with denied applications for approved indications were more liked to die/be removed (44.4% vs. 9.5%, p = 0.49). Although data are needed to properly identify those patients at highest risk for waitlist mortality, standardized criteria or a centralized review board should be adopted to ensure consistency in the granting of exception points. © Copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2012        PMID: 22335632      PMCID: PMC3357462          DOI: 10.1111/j.1600-6143.2011.03969.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  7 in total

1.  Waitlist survival of patients with primary sclerosing cholangitis in the model for end-stage liver disease era.

Authors:  David Goldberg; Benjamin French; Arwin Thomasson; K Rajender Reddy; Scott D Halpern
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

2.  Regional variations in peer reviewed liver allocation under the MELD system.

Authors:  Hector Rodriguez-Luna; Hugo E Vargas; Adyr Moss; Kunam S Reddy; Richard B Freeman; David Mulligan
Journal:  Am J Transplant       Date:  2005-09       Impact factor: 8.086

3.  Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula.

Authors:  Richard B Freeman; Robert G Gish; Ann Harper; Gary L Davis; John Vierling; Leslie Lieblein; Goran Klintmalm; Jamie Blazek; Robert Hunter; Jeffrey Punch
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

4.  Model for end-stage liver disease (MELD) exception for bacterial cholangitis.

Authors:  Gregory J Gores; Robert G Gish; Roshan Shrestha; Russell H Wiesner
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

5.  Liver allocation and distribution: possible next steps.

Authors:  Kenneth Washburn; Elizabeth Pomfret; John Roberts
Journal:  Liver Transpl       Date:  2011-09       Impact factor: 5.799

6.  Liver transplantation in the United States, 1999-2008.

Authors:  P J Thuluvath; M K Guidinger; J J Fung; L B Johnson; S C Rayhill; S J Pelletier
Journal:  Am J Transplant       Date:  2010-04       Impact factor: 8.086

7.  New national liver transplant allocation policy: is the regional review board process fair?

Authors:  Michael D Voigt; Bridget Zimmerman; Daniel A Katz; Stephen C Rayhill
Journal:  Liver Transpl       Date:  2004-05       Impact factor: 5.799

  7 in total
  13 in total

1.  Outcomes of liver transplantation for end-stage biliary disease: A comparative study with end-stage liver disease.

Authors:  Yan-Hua Lai; Wei-Dong Duan; Qiang Yu; Sheng Ye; Nian-Jun Xiao; Dong-Xin Zhang; Zhi-Qiang Huang; Zhan-Yu Yang; Jia-Hong Dong
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

2.  Model for end-stage liver disease-based organ allocation: managing the exceptions to the rules.

Authors:  David S Goldberg; Michael B Fallon
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-14       Impact factor: 11.382

3.  MELD exceptions for portopulmonary hypertension: current policy and future implementation.

Authors:  D S Goldberg; S Batra; S Sahay; S M Kawut; M B Fallon
Journal:  Am J Transplant       Date:  2014-07-01       Impact factor: 8.086

4.  ACG Clinical Guideline: Primary Sclerosing Cholangitis.

Authors:  Keith D Lindor; Kris V Kowdley; M Edwyn Harrison
Journal:  Am J Gastroenterol       Date:  2015-04-14       Impact factor: 10.864

5.  Standardizing MELD Exceptions: Current Challenges and Future Directions.

Authors:  David S Goldberg; Kim M Olthoff
Journal:  Curr Transplant Rep       Date:  2014-12-01

Review 6.  Primary Sclerosing Cholangitis: A Concise Review of Diagnosis and Management.

Authors:  Zachary P Fricker; David R Lichtenstein
Journal:  Dig Dis Sci       Date:  2019-02-06       Impact factor: 3.199

Review 7.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126

8.  Risk of waitlist mortality in patients with primary sclerosing cholangitis and bacterial cholangitis.

Authors:  David S Goldberg; Amanda Camp; Alvaro Martinez-Camacho; Lisa Forman; Brett Fortune; K Rajender Reddy
Journal:  Liver Transpl       Date:  2013-03       Impact factor: 5.799

Review 9.  Management of bacterial infection in the liver transplant candidate.

Authors:  Alberto Ferrarese; Alberto Zanetto; Chiara Becchetti; Salvatore Stefano Sciarrone; Sarah Shalaby; Giacomo Germani; Martina Gambato; Francesco Paolo Russo; Patrizia Burra; Marco Senzolo
Journal:  World J Hepatol       Date:  2018-02-27

10.  [Surgical treatment of primary sclerosing cholangitis : Experiences from 30 years in a single center cohort with 173 consecutive patients].

Authors:  Vittorio Branchi; Tobias J Weismüller; Taotao Zhou; Jonas Henn; Alexander Semaan; Tim R Glowka; Maria Gonzalez-Carmona; Christian Strassburg; Jörg C Kalff; Steffen Manekeller; Hanno Matthaei
Journal:  Chirurg       Date:  2021-02       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.